BidaskClub upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX) from a strong sell rating to a sell rating in a report issued on Saturday morning, BidAskClub reports.

A number of other equities research analysts also recently weighed in on PTGX. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a hold rating to a sell rating in a research note on Tuesday, August 13th. Nomura restated a buy rating and issued a $29.00 target price on shares of Protagonist Therapeutics in a research note on Sunday, August 11th. Svb Leerink restated an outperform rating on shares of Protagonist Therapeutics in a research note on Tuesday, August 13th. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a hold rating to a buy rating and boosted their target price for the company from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, HC Wainwright set a $23.00 target price on shares of Protagonist Therapeutics and gave the company a buy rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $19.60.

PTGX opened at $11.04 on Friday. Protagonist Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $14.36. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.12 and a quick ratio of 4.12. The firm’s fifty day moving average price is $11.64 and its two-hundred day moving average price is $10.74. The company has a market capitalization of $262.54 million, a P/E ratio of -6.34 and a beta of 1.87.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.90). Protagonist Therapeutics had a negative return on equity of 62.50% and a negative net margin of 209.02%. The business had revenue of ($8.19) million for the quarter, compared to analyst estimates of $10.77 million. On average, equities research analysts expect that Protagonist Therapeutics will post -2.65 EPS for the current fiscal year.

In other news, CEO Dinesh V. Ph D. Patel sold 10,792 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total value of $95,509.20. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider David Y. Liu sold 3,395 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total value of $30,045.75. The disclosure for this sale can be found here. 14.20% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Protagonist Therapeutics by 8.8% in the fourth quarter. BlackRock Inc. now owns 260,548 shares of the company’s stock valued at $1,754,000 after buying an additional 21,126 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Protagonist Therapeutics by 33.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 490,267 shares of the company’s stock valued at $3,299,000 after buying an additional 122,250 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Protagonist Therapeutics by 17.2% in the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after buying an additional 5,084 shares during the last quarter. Laurion Capital Management LP raised its holdings in shares of Protagonist Therapeutics by 400.8% in the first quarter. Laurion Capital Management LP now owns 85,641 shares of the company’s stock valued at $1,077,000 after buying an additional 68,541 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Protagonist Therapeutics by 26.5% in the second quarter. Renaissance Technologies LLC now owns 512,300 shares of the company’s stock valued at $6,204,000 after buying an additional 107,300 shares during the last quarter. 61.65% of the stock is owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Recommended Story: What are municipal bonds?

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.